These guidelines underscore the idea that standardization in tissue collection and processing can better support reproducible studies of antitumor immunity.
A four-site research consortium is launching studies of how mutations in the LRKK2 and Parkin genes may cause immune dysfunction that leads to Parkinson disease.
In pediatrics, clinical outcomes from primary brain tumors remain inferior to other cancers. Neurooncologist Neha Patel, MD, discusses game changing advances leading to targeted treatments.
As the medical community struggles to understand and limit the impact of the rapidly evolving COVID-19 pandemic, there are still more questions than answers. In this article, rheumatologists discuss the cytokine storm and experimental therapies, including IL-6 inhibitors and hydroxychloroquine.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new oral immunotherapy drug for peanut allergies will be the No. 4 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
Two analyses of a large Cleveland Clinic cohort confirm the importance of immunotherapy in treating NSCLC brain metastases and reveal critical indicators of efficacy.
The phase 3 KEYNOTE-630 trial has begun enrolling patients with high-risk, locally advanced cutaneous squamous cell carcinoma (cSCC) to evaluate the curative potential of PD-1 inhibitor pembrolizumab.
Despite major progress in treating metastatic clear cell renal cell carcinoma, metastatic non-clear cell renal cell carcinoma remains poorly understood.
A breast oncologist’s take on three new treatment modalities for a difficult-to-treat cancer.
Data from 15 centers in the U.S. and Europe indicate that immunosuppressive therapy should be used more frequently in patients with myelodysplastic syndromes.